Outcome of patients with low‐risk and intermediate‐1‐risk myelodysplastic syndrome after hypomethylating agent failure: A report on behalf of the MDS Clinical Research Consortium
暂无分享,去创建一个
H. Kantarjian | G. Garcia-Manero | T. Kadia | E. Jabbour | N. Daver | D. Steensma | S. O'brien | A. Mishra | J. Lancet | S. Gore | M. Sekeres | E. Padron | G. Roboz | A. List | R. Komrokji | A. DeZern | P. Strati | N. A. Al Ali | Najla H. Al Ali
[1] P. Nguyen,et al. Myelodysplastic syndromes , 2009, Nature Reviews Disease Primers.
[2] J. Lancet,et al. Poor outcome of patients with myelodysplastic syndrome after azacitidine treatment failure. , 2013, Clinical lymphoma, myeloma & leukemia.
[3] P. Fenaux,et al. Outcome of patients with low-risk myelodysplasia after azacitidine treatment failure , 2013, Haematologica.
[4] A. Stamatoullas,et al. Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents , 2013, Leukemia.
[5] Luca Malcovati,et al. Revised international prognostic scoring system for myelodysplastic syndromes. , 2012, Blood.
[6] B. Esterni,et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] Benjamin L Ebert,et al. Unraveling the molecular pathophysiology of myelodysplastic syndromes. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] Alan Agresti,et al. Categorical Data Analysis , 2003 .
[9] J. Issa,et al. Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy , 2010, Cancer.
[10] J. Sierra,et al. Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia. , 2010, Blood.
[11] Valeria Santini,et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. , 2009, The Lancet. Oncology.
[12] J. Issa,et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System , 2008, Cancer.
[13] J. Issa,et al. Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine , 2008, Leukemia & lymphoma.
[14] H. Kantarjian,et al. A prognostic score for patients with lower risk myelodysplastic syndrome , 2008, Leukemia.
[15] J. Issa,et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. , 2007, Blood.
[16] B. Cheson,et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. , 2006, Blood.
[17] John M Bennett,et al. Decitabine improves patient outcomes in myelodysplastic syndromes , 2006, Cancer.
[18] J. Holland,et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] T Hamblin,et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.
[20] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[21] D.,et al. Regression Models and Life-Tables , 2022 .